Open AccessCost-Effectiveness Analysis from a Societal Perspective of Recurrence Index for Distant Recurrence (RecurIndex) in Women with Hormone Receptor-Positive and HER2-Negative Early-Stage Breast Cancer
Author(s) -
Nicolas Pennarun,
Chiu JY,
Chang HC,
Huang SL,
Cheng SHC
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s339549
Subject(s) - medicine , breast cancer , oncology , stage (stratigraphy) , gynecology , cancer , demography , biology , paleontology , sociology
A clinical-genomic prognostic multigene panel (RI-DR assay, RecurIndex ® ), predicting the risk level of distant recurrence (DR) in early-stage breast cancer (EBC) patients with an Asian background, has been validated as a valuable tool for identifying high-risk patients to develop distant recurrence (metastasis). Although the clinical benefit of adjuvant chemotherapy from the assay's prediction is already proved, its affordability remains uncertain. This study is the first time in which the long-term cost-effectiveness of the RI-DR assay is evaluated.